TP53 and cancer: We describe molecular and immune features that define subgroups of PSC with disparate genomic and immunogenic features as well as distinct clinical outcomes.<h4>Results</h4>In total, 27 canonical cancer gene mutations were identified, with <i>TP53</i> the most frequently mutated gene, followed by <i>KRAS</i>.